In a significant development, Nxera Pharma Group has secured a substantial investment of $15 million from Neurocrine Biosciences following the dosing of the first patient in the Phase 3 trial of NBI-1117568. This strategic alliance marks a crucial milestone in the discovery, development, and potential commercialization of innovative pharmaceutical products. However, investors should be aware […]